Acute exacerbations of progressive-fibrosing interstitial lung diseases

Martin Kolb, Benjamin Bondue, Alberto Pesci, Yasunari Miyazaki, Jin Woo Song, Nitin Y. Bhatt, John T. Huggins, Justin Oldham, Maria L. Padilla, Jesse Roman, Shane Shapera

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Acute exacerbation of interstitial lung disease (ILD) is associated with a poor prognosis and high mortality. Numerous studies have documented acute exacerbation in idiopathic pulmonary fibrosis (IPF), but less is known about these events in other ILDs that may present a progressive-fibrosing phenotype. We propose defining acute exacerbation as an acute, clinically significant respiratory deterioration, typically less than 1 month in duration, together with computerised tomography imaging showing new bilateral glass opacity and/or consolidation superimposed on a background pattern consistent with fibrosing ILDs. Drawing on observations in IPF, it is suspected that epithelial injury or proliferation and autoimmunity are risk factors for acute exacerbation in ILDs that may present a progressive-fibrosing phenotype, but further studies are required. Current acute exacerbation management strategies are based on recommendations in IPF, but no randomised controlled trials of acute exacerbation management have been performed. Although there are no formal strategies to prevent the development of acute exacerbation, possible approaches include antifibrotic drugs (such as nintedanib and pirfenidone), and minimising exposure to infection, airborne irritants and pollutants. This review discusses the current knowledge of acute exacerbation of ILDs that may present a progressive-fibrosing phenotype and acknowledges limitations of the data available.

Original languageEnglish (US)
Article number180071
JournalEuropean Respiratory Review
Volume27
Issue number150
DOIs
StatePublished - Jan 1 2018

Fingerprint

Idiopathic Pulmonary Fibrosis
Interstitial Lung Diseases
Phenotype
Irritants
Autoimmunity
Glass
Randomized Controlled Trials
Tomography
Mortality
Wounds and Injuries
Infection
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Kolb, M., Bondue, B., Pesci, A., Miyazaki, Y., Song, J. W., Bhatt, N. Y., ... Shapera, S. (2018). Acute exacerbations of progressive-fibrosing interstitial lung diseases. European Respiratory Review, 27(150), [180071]. https://doi.org/10.1183/16000617.0071-2018

Acute exacerbations of progressive-fibrosing interstitial lung diseases. / Kolb, Martin; Bondue, Benjamin; Pesci, Alberto; Miyazaki, Yasunari; Song, Jin Woo; Bhatt, Nitin Y.; Huggins, John T.; Oldham, Justin; Padilla, Maria L.; Roman, Jesse; Shapera, Shane.

In: European Respiratory Review, Vol. 27, No. 150, 180071, 01.01.2018.

Research output: Contribution to journalReview article

Kolb, M, Bondue, B, Pesci, A, Miyazaki, Y, Song, JW, Bhatt, NY, Huggins, JT, Oldham, J, Padilla, ML, Roman, J & Shapera, S 2018, 'Acute exacerbations of progressive-fibrosing interstitial lung diseases', European Respiratory Review, vol. 27, no. 150, 180071. https://doi.org/10.1183/16000617.0071-2018
Kolb M, Bondue B, Pesci A, Miyazaki Y, Song JW, Bhatt NY et al. Acute exacerbations of progressive-fibrosing interstitial lung diseases. European Respiratory Review. 2018 Jan 1;27(150). 180071. https://doi.org/10.1183/16000617.0071-2018
Kolb, Martin ; Bondue, Benjamin ; Pesci, Alberto ; Miyazaki, Yasunari ; Song, Jin Woo ; Bhatt, Nitin Y. ; Huggins, John T. ; Oldham, Justin ; Padilla, Maria L. ; Roman, Jesse ; Shapera, Shane. / Acute exacerbations of progressive-fibrosing interstitial lung diseases. In: European Respiratory Review. 2018 ; Vol. 27, No. 150.
@article{e7c7cacc590342bc8873f3bfe77599cb,
title = "Acute exacerbations of progressive-fibrosing interstitial lung diseases",
abstract = "Acute exacerbation of interstitial lung disease (ILD) is associated with a poor prognosis and high mortality. Numerous studies have documented acute exacerbation in idiopathic pulmonary fibrosis (IPF), but less is known about these events in other ILDs that may present a progressive-fibrosing phenotype. We propose defining acute exacerbation as an acute, clinically significant respiratory deterioration, typically less than 1 month in duration, together with computerised tomography imaging showing new bilateral glass opacity and/or consolidation superimposed on a background pattern consistent with fibrosing ILDs. Drawing on observations in IPF, it is suspected that epithelial injury or proliferation and autoimmunity are risk factors for acute exacerbation in ILDs that may present a progressive-fibrosing phenotype, but further studies are required. Current acute exacerbation management strategies are based on recommendations in IPF, but no randomised controlled trials of acute exacerbation management have been performed. Although there are no formal strategies to prevent the development of acute exacerbation, possible approaches include antifibrotic drugs (such as nintedanib and pirfenidone), and minimising exposure to infection, airborne irritants and pollutants. This review discusses the current knowledge of acute exacerbation of ILDs that may present a progressive-fibrosing phenotype and acknowledges limitations of the data available.",
author = "Martin Kolb and Benjamin Bondue and Alberto Pesci and Yasunari Miyazaki and Song, {Jin Woo} and Bhatt, {Nitin Y.} and Huggins, {John T.} and Justin Oldham and Padilla, {Maria L.} and Jesse Roman and Shane Shapera",
year = "2018",
month = "1",
day = "1",
doi = "10.1183/16000617.0071-2018",
language = "English (US)",
volume = "27",
journal = "European Respiratory Review",
issn = "0905-9180",
publisher = "European Respiratory Society",
number = "150",

}

TY - JOUR

T1 - Acute exacerbations of progressive-fibrosing interstitial lung diseases

AU - Kolb, Martin

AU - Bondue, Benjamin

AU - Pesci, Alberto

AU - Miyazaki, Yasunari

AU - Song, Jin Woo

AU - Bhatt, Nitin Y.

AU - Huggins, John T.

AU - Oldham, Justin

AU - Padilla, Maria L.

AU - Roman, Jesse

AU - Shapera, Shane

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Acute exacerbation of interstitial lung disease (ILD) is associated with a poor prognosis and high mortality. Numerous studies have documented acute exacerbation in idiopathic pulmonary fibrosis (IPF), but less is known about these events in other ILDs that may present a progressive-fibrosing phenotype. We propose defining acute exacerbation as an acute, clinically significant respiratory deterioration, typically less than 1 month in duration, together with computerised tomography imaging showing new bilateral glass opacity and/or consolidation superimposed on a background pattern consistent with fibrosing ILDs. Drawing on observations in IPF, it is suspected that epithelial injury or proliferation and autoimmunity are risk factors for acute exacerbation in ILDs that may present a progressive-fibrosing phenotype, but further studies are required. Current acute exacerbation management strategies are based on recommendations in IPF, but no randomised controlled trials of acute exacerbation management have been performed. Although there are no formal strategies to prevent the development of acute exacerbation, possible approaches include antifibrotic drugs (such as nintedanib and pirfenidone), and minimising exposure to infection, airborne irritants and pollutants. This review discusses the current knowledge of acute exacerbation of ILDs that may present a progressive-fibrosing phenotype and acknowledges limitations of the data available.

AB - Acute exacerbation of interstitial lung disease (ILD) is associated with a poor prognosis and high mortality. Numerous studies have documented acute exacerbation in idiopathic pulmonary fibrosis (IPF), but less is known about these events in other ILDs that may present a progressive-fibrosing phenotype. We propose defining acute exacerbation as an acute, clinically significant respiratory deterioration, typically less than 1 month in duration, together with computerised tomography imaging showing new bilateral glass opacity and/or consolidation superimposed on a background pattern consistent with fibrosing ILDs. Drawing on observations in IPF, it is suspected that epithelial injury or proliferation and autoimmunity are risk factors for acute exacerbation in ILDs that may present a progressive-fibrosing phenotype, but further studies are required. Current acute exacerbation management strategies are based on recommendations in IPF, but no randomised controlled trials of acute exacerbation management have been performed. Although there are no formal strategies to prevent the development of acute exacerbation, possible approaches include antifibrotic drugs (such as nintedanib and pirfenidone), and minimising exposure to infection, airborne irritants and pollutants. This review discusses the current knowledge of acute exacerbation of ILDs that may present a progressive-fibrosing phenotype and acknowledges limitations of the data available.

UR - http://www.scopus.com/inward/record.url?scp=85058911532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058911532&partnerID=8YFLogxK

U2 - 10.1183/16000617.0071-2018

DO - 10.1183/16000617.0071-2018

M3 - Review article

C2 - 30578331

AN - SCOPUS:85058911532

VL - 27

JO - European Respiratory Review

JF - European Respiratory Review

SN - 0905-9180

IS - 150

M1 - 180071

ER -